PALB2 Effort

Breast Cancer Treatment in Women with PALB2 Mutations

A mutation in the PALB2 gene raises the risk for developing certain types of cancer. For women with a PALB2 mutation, the lifetime risk of breast cancer is ~35-40% compared to 12% in the general population. There may also be other increased cancer risks, including pancreatic and male breast cancer.


 

OUR MISSION

To determine the best treatment for women with a PALB2 mutation and breast cancer. Through a better understanding, we can personalize breast cancer treatment to increase survival, and determine how to best manage at risk family members to detect cancer early or prevent it.

 

 

WHO IS ELIGIBLE TO PARTICIPATE IN THIS STUDY?

  • Women with a pathogenic or likely pathogenic PALB2 mutation with or without a personal history of cancer


WHAT WILL I BE ASKED TO DO?

  • Complete a baseline questionnaire, either on paper or online
  • Complete a medical record release so the study investigators can collect information on genetic test results, breast cancer pathology, and treatment
  • Agree to be contacted every two years to update your information


HOW DO I JOIN?

If you would like to participate in this PALB2 effort, please enroll in the Inherited Cancer Registry (ICARE) Initiative now by clicking the link below. Once enrolled, you will be asked to complete a baseline questionnaire and a study team member will inform you of any additional information that may be needed for this focused effort.

Enroll in ICARE now!

Please note if you are already an ICARE participant with a PALB2 mutation, we have already collected much of the information needed from you to contribute to this focused effort. We will inform you of any additional information that may be needed for study purposes.


WHY IS YOUR PARTICIPATION IMPORTANT?

Learning more about breast cancer among women with a PALB2 mutation will help to better understand: 114335516

  • If women with breast cancer have an increased risk of developing a new breast cancer
  • The best treatment for women with a PALB2 mutation and breast cancer to increase the chance of survival
  • How healthy family members who also carry a PALB2 mutation can best manage their cancer risks (through screening or preventive surgery, etc.)


WHY IS IT IMPORTANT TO LEARN MORE ABOUT THE BREAST CANCERS THAT OCCUR IN WOMEN WITH A PALB2
MUTATION?

Currently, we know little about breast cancers that occur in women with a PALB2 mutation. Thus, it is important:

  • To figure out how to best treat women with PALB2 who develop breast cancer
  • To help figure out how women with PALB2 without breast cancer can best manage their cancer risks and be proactive about their health


WHO ARE WE?

We are a group of scientists who study hereditary breast cancer. Our research focuses on the prevention and treatment of breast cancer in women with a genetic mutation. We have studied the treatment of breast cancer in women with a BRCA1 or BRCA2 mutation and how treatment can be personalized for these women. We  now want to understand if we should also personalize treatment for women with a PALB2 mutation who develop breast cancer. This study is a collaboration between Women’s College Hospital in Toronto, Canada (Drs. Kelly Metcalfe and Steven Narod) and Vanderbilt-Ingram Cancer Center in Nashville, Tennessee (Dr. Tuya Pal).

Are you a provider interested in helping with this effort? If so, please click below.

Letter of Invitation to Providers


If you are interested in learning more about PALB2, please click here to read articles previously featured in the ICARE newsletter. 

For more information about this research study,
please contact our study team.

US: (615) 875-2444
  Canada: (416) 351-3800 x2761
Email: ICARE@InheritedCancer.net